4suxxess welcomes you!



Setup. Growth. Restructuring. Turnaround.

 

At 4suxxess, we offer you a team of business architects dedicated to support your company with services designed to enable you to enhance your competitiveness - whether it’s overcoming barriers to success or developing markets locally and globally.

4suxxess provides experienced executive professionals, with the right skill sets to ensure success in challenging assignments and projects.


PharmaTimes: News RSS

ABPI suspends Astellas UK for a further year (Fri, 23 Jun 2017)
Astellas UK’s membership of the Association of the British Pharmaceutical Industry has been suspended for a further 12 months because of a number of “serious breaches” of the Code of Practice.
>> Read More

NICE turnaround for AstraZeneca’s COPD drug Daxas (Fri, 23 Jun 2017)
AstraZeneca’s Daxas is now likely to be routinely available on the NHS to patients with chronic obstructive pulmonary disease (COPD), after new evidence helped persuade cost regulators that the drug is value for money in this setting.
>> Read More

US nod for CSL Behring’s HAE prevention therapy (Fri, 23 Jun 2017)
US regulators have approved CSL Behring’s Haegarda, the first C1 esterase inhibitor for subcutaneous administration to prevent hereditary angioedema (HAE) attacks in adolescent and adults
>> Read More

Green light for Novartis’ lung cancer combination therapy (Fri, 23 Jun 2017)
Novartis’ combination therapy Tafinlar + Mekinist has won approval from the US Food and Drug Administration to treat patients with metastatic non-small cell lung cancer (NSCLC) carrying the BRAF V600E mutation.
>> Read More

NHS England re-opens innovation accelerator scheme (Fri, 23 Jun 2017)
NHS England is again issuing a call for the world’s “best healthcare innovations” to improve frontline patient care in a further round of the NHS Innovation Accelerator programme.
>> Read More